Citations

Clear

3942 citation(s) found for "To, Van".

Micromagnetic Neural Stimulation and Spintronic Neural Sensing
Tonini, Denis , Hopper, Matthew S. , Goyal, Abhinav , Sanger, Zachary , Faramarzi, Sadegh , Shiao, Maple, Helden, Dusty Van , Wu, Kai , Keirstead, Susan A. , Netoff, Théoden I. , Low, Walter C. , Osborn, John, Bennet, Kevin E. , Lee, Kendall H. , Shin, Hojin , Wang, Jian-Ping , Saha, Renata , Yuen, Jason , Oh, Yoonbae , Bloom, Robert P. , Benally, Onri Jay

Mayo Clinic

2024 IEEE International Magnetic Conference - Short papers (INTERMAG Short papers) | July 5, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-2

10.1109/intermagshortpapers61879.2024.10576875 Get It

Clinical Characteristics and Mechanisms of Acute Myocarditis
Linthout, Sophie Van , Kraus, Sarah , Ntusi, Ntobeko , Heymans, Stephane , Van Linthout, Sophie , Kraus, Sarah Mignon , Cooper, Leslie T , Ntusi, Ntobeko A B , Heymans, Stéphane , Cooper, Leslie T.

Mayo Clinic

Circulation Research | July 4, 2024 | Volume: 135 | Issue: 2 | Pages: 397-411

10.1161/circresaha.124.324674 | PMID 38963866 Get It

Myocarditis is defined by an immune response to infection or injury, most commonly identified after a viral infection or recent exposure to cardiotoxins or drugs. Classic myocarditis may also result from the activation of the immune system by self-antigens without an exogenous trigger. Pathogenic variants of genes encoding sarcolemmal and desmosomal proteins are present in 4% to 44% of myocarditis patients and may relate to persistent cardiac dysfunction and arrhythmias. The most common clinical presentation is acute chest pain resembling an ischemic infarction or pericarditis. Heart failure and syncope from tachy- or brady-arrhythmias are features of a complicated clinical course with substantial risk of future cardiovascular events and death. High-sensitivity troponin, ECG, and echocardiograms are useful but lack sufficient sensitivity and specificity to confirm the diagnosis. Cardiovascular magnetic resonance is indicated to confirm myocarditis in low-risk, uncomplicated cases. Endomyocardial biopsy is indicated to guide therapy in high-risk scenarios. In this review, we discuss the clinical aspects, pathogenesis, genetic susceptibility, and management of uncomplicated, complicated, and fulminant myocarditis related to viral injury. We identify gaps in understanding and suggest prime research questions in the pathogenesis, diagnosis, and treatment of acute myocarditis. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05335928.
Stereotactic depth electrode placement for chronic subthreshold cortical stimulation: surgical technique video
Harrison, Daniel , Oushy, Soliman , Harrison, Daniel Jeremiah, Oushy, Soliman H , Gregg, Nicholas M. , Lundstrom, Brian N. , Gompel, Jamie J. Van

Mayo Clinic

Neurosurgical Focus: Video | July 3, 2024 | Volume: 11 | Issue: 1 | Pages: V10

10.3171/2024.4.focvid2422 | PMID 38957423 Get It

Neurostimulation is an increasingly common treatment option for medically intractable epilepsy. SANTE (Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy) and Responsive Neurostimulation (RNS) System are landmark neurostimulation trials that utilized either duty cycle or a responsive stimulation paradigm. A seizure-free outcome is rarely observed with responsive and duty cycle neurostimulation devices. Chronic subthreshold cortical stimulation (CSCS) is a promising treatment for adult drug-resistant epilepsy involving eloquent cortex and has demonstrated safety and efficacy. Herein, the authors describe the surgical technique as well as details of stimulation programming involved in CSCS placement to facilitate the adoption of this promising treatment. The video can be found here: https://stream.cadmore.media/r10.3171/2024.4.FOCVID2422
Utility of Targeted Sequencing Compared to FISH for Detection of Chronic Lymphocytic Leukemia Copy Number Alterations
Wiedmeier, Julia E. , McCabe, Chantal E. , O’Brien, Daniel R. , Jessen, Erik , Campos, Cecília Bonolo de , Waller, Rosalie G. , Allmer, Cristine, Rabe, Kari G. , Cerhan, James R. , Kay, Neil E. , Yan, Huihuang , Dyke, Daniel L. Van , Griffin, R. L. , Wiedmeier-Nutor, Julia E , Bonolo de Campos, Cecilia, Griffin, Rosalie, Chaffee, Kari G. , Cerhan, James R , Kay, Neil E , Van Dyke, Daniel L, Jessen, Erik , Waller, Rosalie G , Griffin, Rosalie , Boddicker, Nicholas , Parikh, Sameer A. , Slager, Susan L. , Braggio, Esteban

Mayo Clinic

Cancers | July 3, 2024 | Volume: 16 | Issue: 13 | Pages: 2450

10.3390/cancers16132450 | PMID 39001512 Get It

Chronic lymphocytic leukemia (CLL) is characterized by multiple copy number alterations (CNAs) and somatic mutations that are central to disease prognosis, risk stratification, and mechanisms of therapy resistance. Fluorescence in situ hybridization (FISH) panels are widely used in clinical applications as the gold standard for screening prognostic chromosomal abnormalities in CLL. DNA sequencing is an alternative approach to identifying CNAs but is not an established method for clinical CNA screening. We sequenced DNA from 509 individuals with CLL or monoclonal B-cell lymphocytosis (MBL), the precursor to CLL, using a targeted sequencing panel of 59 recurrently mutated genes in CLL and additional amplicons across regions affected by clinically relevant CNAs [i.e., del(17p), del(11q), del(13q), and trisomy 12]. We used the PatternCNV algorithm to call CNA and compared the concordance of calling clinically relevant CNAs by targeted sequencing to that of FISH. We found a high accuracy of calling CNAs via sequencing compared to FISH. With FISH as the gold standard, the specificity of targeted sequencing was >95%, sensitivity was >86%, positive predictive value was >90%, and negative predictive value was >84% across the clinically relevant CNAs. Using targeted sequencing, we were also able to identify other common CLL-associated CNAs, including del(6q), del(14q), and gain 8q, as well as complex karyotype, defined as the presence of 3 or more chromosomal abnormalities, in 26 patients. In a single and cost-effective assay that can be performed on stored DNA samples, targeted sequencing can simultaneously detect CNAs, somatic mutations, and complex karyotypes, which are all important prognostic features in CLL.
A Cadaveric Feasibility Study of the Biportal Endoscopic Transfrontal Sinus Approach: A Minimally Invasive Approach to the Anterior Cranial Fossa
Sáez-Alegre, Miguel , Jean, Walter C. , Link, Michael J., Celda, María Peris, Torregrossa, Fábio , Jean, Walter C , Peris Celda, Maria, Pinheiro Neto, Carlos D, Morshed, Ramin A. , Piper, Keaton , Gompel, Jamie J. Van , Pinheiro‐Neto, Carlos

Mayo Clinic

Operative Neurosurgery | July 2, 2024 | Volume: 28 | Issue: 2 | Pages: 175-182

10.1227/ons.0000000000001249 | PMID 38953666 Get It

BACKGROUND AND OBJECTIVES: The trans-sinus transglabellar and bifrontal approaches offer direct access to the anterior cranial fossa. However, these approaches present potential drawbacks. We propose the biportal endoscopic transfrontal sinus (BETS) approach, adapting endoscopic endonasal approach (EEA) techniques for minimally invasive access to the anterior fossa, reducing tissue manipulation, venous sacrifice, and brain retraction. METHODS: Six formalin specimens were used. BETS approach involves 2 incisions over the medial aspect of both eyebrows from the supraorbital notch to the medial end of the eyebrow. A unilateral pedicled pericranial flap is harvested. A craniotomy through the anterior table of the frontal sinus (FS) and a separate craniotomy through the posterior table are performed. Two variants of the approach (preservative vs cranialization) are described for opening and reconstruction of the FS based on the desired pathology to access. Bone flap replacement can be performed with titanium plates and filling of the external table defect with bone cement. RESULTS: Like in EEA, this approach provides access for endoscope and multiple working instruments to be used simultaneously. The approach allows wide access to the anterior cranial fossa, subfrontal, and interhemispheric corridors, all the way up to the suprachiasmatic corridor and through the lamina terminalis to the third ventricle. BETS provides direct access to the anterior fossa, minimizing the level of frontal lobe retraction and providing potentially less tissue disruption and improved cosmesis. Cerebrospinal fluid fistula risk remains one of the major concerns as the narrow corridor limits achieving a watertight closure which can be mitigated with a pedicled flap. Mucocele risk is minimized with full cranialization or reconstruction of the FS. CONCLUSION: The BETS approach is a minimally invasive approach that translates the concepts of EEA to the FS. It allows excellent access to the anterior cranial fossa structures with minimal frontal lobe retraction.
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT
Tarantino, Paolo , Tayob, Nabihah , Villacampa, Guillermo , Dang, Chau T. , Isakoff, Steven J. , Valero, Vicente , Faggen, Meredith, Mulvey, Therese M. , Bose, Ron , Weckstein, Douglas, Reeder‐Hayes, Katherine E. , Ramaswamy, Bhuvaneswari , Zuckerman, Dan Sayam , Hart, Lowell L., Gadi, Vijayakrishna K. , Constantine, Michael, Cheng, Kit , Garrett, Audrey Merrill, Albain, Kathy S. , DeFusco, Patricia, Ardman, Blair, Nanda, Rita , Jankowitz, Rachel C. , Rimawi, Mothaffar F. , Pohlmann, Paula R. , Poznak, Catherine Van , Forero‐Torres, Andres , Liu, Minetta C. , Ruddy, Kathryn J. , Waks, Adrienne G., DeMeo, Michelle K. , Burstein, Harold J. , Dell’Orto, Patrizia , Russo, Leila, Krause, Emma , Newhouse, Daniel , Schneider, Bryan P. , Krop, Ian E. , Tolaney, Sara M. , Curigliano, Giuseppe , Hui, Winnie W. , Kirkup, Christian , Viale, Giuseppe , Prat, Aleix , Isakoff, Steven J , Mulvey, Therese Marie , Bose, Ron , Wolff, Antonio C , Reeder-Hayes, Katherine , Rugo, Hope S , Zuckerman, Dan , Gadi, Vijayakrishna K , Cheng, Kit , Marcom, Paul Kelly , Albain, Kathy , Tung, Nadine , Nanda, Rita , Jankowitz, Rachel C , Rimawi, Mothaffar , Abramson, Vandana G , Van Poznak, Catherine , Forero-Torres, Andres , Liu, Minetta , Ruddy, Kathryn J , Burstein, Harold J , Partridge, Ann H , Krause, Emma , Kurt, Busem Binboğa , Mittendorf, EA , Schneider, Bryan , Prat, Aleix , Winer, Eric , Krop, Ian E , Tolaney, Sara , Prat, Aleix , Curigliano, Giuseppe , Pohlmann, Paula , Yardley, Denise Aysel , Wolff, Antonio C. , Rugo, Hope S. , Tung, Nadine , Abramson, Vandana G. , Waks, Adrienne G. , Partridge, Ann H. , Winer, Eric P. , Barroso‐Sousa, Romualdo , DiLullo, Molly K. , Zheng, Yue

Mayo Clinic

Journal of Clinical Oncology | June 27, 2024 | Volume: 42 | Issue: 31 | Pages: 3652-3665

10.1200/jco.23.02170 | PMID 38935923 Get It

PURPOSE Long-term outcomes of patients with stage I human epidermal growth factor receptor 2 (HER2)–positive breast cancer receiving adjuvant trastuzumab emtansine (T-DM1) remain undefined, and prognostic predictors represent an unmet need. METHODS In the ATEMPT phase II trial, patients with stage I centrally confirmed HER2-positive breast cancer were randomly assigned 3:1 to adjuvant T-DM1 for 1 year or paclitaxel plus trastuzumab (TH). Coprimary objectives were to compare the incidence of clinically relevant toxicities between arms and to evaluate invasive disease-free survival (iDFS) with T-DM1. Correlative analyses included the HER2DX genomic tool, multiomic evaluations of HER2 heterogeneity, and predictors of thrombocytopenia. RESULTS After a median follow-up of 5.8 years, 11 iDFS events were observed in the T-DM1 arm, consistent with a 5-year iDFS of 97.0% (95% CI, 95.2 to 98.7). At 5 years, the recurrence-free interval (RFI) was 98.3% (95% CI, 97.0 to 99.7), the overall survival was 97.8% (95% CI, 96.3 to 99.3), and the breast cancer-specific survival was 99.4% (95% CI, 98.6 to 100). Comparable iDFS was observed with T-DM1 irrespective of tumor size, hormone receptor status, centrally determined HER2 immunohistochemical score, and receipt of T-DM1 for more or less than 6 months. Although ATEMPT was not powered for this end point, the 5-year iDFS in the TH arm was 91.1%. Among patients with sufficient tissue for HER2DX testing (n = 187), 5-year outcomes significantly differed according to HER2DX risk score, with better RFI (98.1% v 81.8%, hazard ratio [HR], 0.10, P = .01) and iDFS (96.3% v 81.8%, HR, 0.20, P = .047) among patients with HER2DX low-risk versus high-risk tumors, respectively. CONCLUSION Adjuvant T-DM1 for 1 year leads to outstanding long-term outcomes for patients with stage I HER2-positive breast cancer. A high HER2DX risk score predicted a higher risk of recurrence in ATEMPT.
Ten‐Year Trend of Oral Anticoagulation Use in Postoperative and Nonpostoperative Atrial Fibrillation in Routine Clinical Practice
Yao, Xiaoxi , Houten, Holly K. Van , Siontis, Konstantinos C. , Friedman, Paul A. , McBane, Robert D. , Gersh, Bernard J. , Noseworthy, Peter A. , Van Houten, Holly K , McBane, Robert , Noseworthy, Peter A , Gersh, Bernard J , Yao, Xiaoxi

Mayo Clinic

Journal of the American Heart Association | June 27, 2024 | Volume: 13 | Issue: 13 | Pages: No page available

10.1161/jaha.124.035708 | PMID 38934887 Get It

Background The study aimed to describe the patterns and trends of initiation, discontinuation, and adherence of oral anticoagulation (OAC) in patients with new‐onset postoperative atrial fibrillation (POAF), and compare with patients newly diagnosed with non‐POAF. Methods and Results This retrospective cohort study identified patients newly diagnosed with atrial fibrillation or flutter between 2012 and 2021 using administrative claims data from OptumLabs Data Warehouse. The POAF cohort included 118 366 patients newly diagnosed with atrial fibrillation or flutter within 30 days after surgery. The non‐POAF cohort included the remaining 315 832 patients who were newly diagnosed with atrial fibrillation or flutter but not within 30 days after a surgery. OAC initiation increased from 28.9% to 44.0% from 2012 to 2021 in POAF, and 37.8% to 59.9% in non‐POAF; 12‐month medication adherence increased from 47.0% to 61.8% in POAF, and 59.7% to 70.4% in non‐POAF. The median time to OAC discontinuation was 177 days for POAF, and 242 days for non‐POAF. Patients who saw a cardiologist within 90 days of the first atrial fibrillation or flutter diagnosis, regardless of POAF or non‐POAF, were more likely to initiate OAC (odds ratio, 2.92 [95% CI, 2.87–2.98]; P <0.0001), adhere to OAC (odds ratio, 1.08 [95% CI, 1.04–1.13]; P <0.0001), and less likely to discontinue (odds ratio, 0.83 [95% CI, 0.82–0.85]; P <0.0001) than patients who saw a surgeon or other specialties. Conclusions The use of and adherence to OAC were higher in non‐POAF patients than in POAF patients, but they increased over time in both groups. Patients managed by cardiologists were more likely to use and adhere to OAC, regardless of POAF or non‐POAF.
Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study
Jain, Tania , Estrada‐Merly, Noel, Salas, María Queralt , Kim, Soyoung , DeVos, Jakob D. , Chen, Min , Fang, Xi , Kumar, Rajat , Elmariah, Hany , Aljurf, Mahmoud , Badar, Talha , Ballen, Karen K. , Bredeson, Christopher , DeFilipp, Zachariah , Farhadfar, Nosha , Farhan, Shatha , Gandhi, Arpita , Ganguly, Siddhartha , Hamilton, Betty K. , Inamoto, Yoshihiro , Jamy, Omer , Kharfan‐Dabaja, Mohamed A. , Krem, Maxwell M. , Lad, Deepesh , Malone, Adriana K. , Pawarode, Attaphol , Poel, Marjolein van der , Rizzieri, David A. , Savoie, Mary Lynn , Seo, Sachiko , Solh, Melhem , Üstün, Celalettin , Verdonck, Leo F. , Wirk, Baldeep , Bejanyan, Nelli , Jones, Richard J., Nakamura, Ryotaro , Scott, Bart L. , Saber, Wael , Gupta, Vikas , Salas, M Queralt , Elmariah, Hany , Bacher, Ulrike , Badar, Talha , Bhatt, Vijaya Raj , DeFilipp, Zachariah , Dholaria, Bhagirathbhai R , Farhan, Shatha , Hamad, Nada , Hamilton, Betty K , Inamoto, Yoshihiro , Jamy, Omer , Juckett, Mark , Kharfan-Dabaja, Mohamed A , Krem, Maxwell M , Al Malki, Monzr M , Malone, Adriana K , Murthy, Hemant S , Patel, Sagar , Perales, Miguel-Angel , Ringden, Olov , Rovó, Alicia , Savani, Bipin N , Savoie, Mary Lynn , Seo, Sachiko , Ustun, Celalettin , Verdonck, Leo F , Bejanyan, Nelli , Nishihori, Taiga , Nakamura, Ryotaro , Scott, Bart , Gupta, Vikas , Jain, Tania , Kim, Soyoung , Andrade‐Campos, Marcio , Agrawal, Vaibhav , Badawy, Sherif M. , Beitinjaneh, Amer , Bhatt, Vijaya Raj , Dholaria, Bhagirathbhai , Gergis, Usama , Grunwald, Michael R. , Hamad, Nada , Iqbal, Madiha , Liesveld, Jane L. , Malki, Monzr M. Al , Murthy, Hemant S. , Ortí, Guillermo, Patel, Sagar S. , Perales, Miguel‐Angel , Ringdén, Olle , Savani, Bipin N. , Wingard, John R. , Nishihori, Taiga , Oran, Betül

Mayo Clinic

Blood Advances | June 25, 2024 | Volume: 8 | Issue: 16 | Pages: 4281-4293

10.1182/bloodadvances.2024013451 | PMID 38916866 Get It

Abstract We evaluate the impact of donor types on outcomes of hematopoietic cell transplantation (HCT) in myelofibrosis, using the Center for International Blood and Marrow Transplant Research registry data for HCTs done between 2013 and 2019. In all 1597 patients, the use of haploidentical donors increased from 3% in 2013 to 19% in 2019. In study-eligible 1032 patients who received peripheral blood grafts for chronic-phase myelofibrosis, 38% of recipients of haploidentical HCT were non-White/Caucasian. Matched sibling donor (MSD)–HCTs were associated with superior overall survival (OS) in the first 3 months (haploidentical hazard ratio [HR], 5.80 [95% confidence interval (CI), 2.52-13.35]; matched unrelated (MUD) HR, 4.50 [95% CI, 2.24-9.03]; mismatched unrelated HR, 5.13 [95% CI, 1.44-18.31]; P &lt; .001). This difference in OS aligns with lower graft failure with MSD (haploidentical HR, 6.11 [95% CI, 2.98-12.54]; matched unrelated HR, 2.33 [95% CI, 1.20-4.51]; mismatched unrelated HR, 1.82 [95% CI, 0.58-5.72]). There was no significant difference in OS among haploidentical, MUD, and mismatched unrelated donor HCTs in the first 3 months. Donor type was not associated with differences in OS beyond 3 months after HCT, relapse, disease-free survival, or OS among patients who underwent HCT within 24 months of diagnosis. Patients who experienced graft failure had more advanced disease and commonly used nonmyeloablative conditioning. Although MSD-HCTs were superior, there is no significant difference in HCT outcomes from haploidentical and MUDs. These results establish haploidentical HCT with posttransplantation cyclophosphamide as a viable option in myelofibrosis, especially for ethnic minorities underrepresented in the donor registries.
Predictors of Durable Remission After Successful Surgery for Cushing Disease: Results From the Multicenter RAPID Registry
Tenhoeve, Sam , Evans, James, Collopy, Sarah , Delery, William , Pacione, Donato , Silverstein, Julie , Gardner, Paul A. , Rotman, Lauren E., Yuen, Kevin C.J. , Barkhoudarian, Garni , Fernandez‐Miranda, Juan C. , Benjamin, Carolina , Kshettry, Varun R. , Zada, Gabriel , Catalino, Michael P. , Little, Andrew S. , Karsy, Michael , Van Gompel, Jamie, Karsy, Michael , Findlay, Matthew C. , Alt, Jeremiah A. , Rennert, Robert C , Couldwell, William T. , Evans, James, Kim, Won Bae , Kim, Albert H. , Chicoine, Michael , Gompel, Jamie J. Van

Mayo Clinic

Neurosurgery | June 21, 2024 | Volume: 95 | Issue: 4 | Pages: 761-769

10.1227/neu.0000000000003042 | PMID 39293794 Get It

BACKGROUND AND OBJECTIVE: Cushing disease (CD) affects mortality and quality of life along with limited long-term remission, underscoring the need to better identify recurrence risk. The identification of surgical or imaging predictors for CD remission after transsphenoidal surgery has yielded some inconsistent results and has been limited by single-center, single-surgeon, or meta-analyses studies. We sought to evaluate the multicenter Registry of Adenomas of the Pituitary and Related Disorders (RAPID) database of academic US pituitary centers to assess whether robust nonhormonal recurrence predictors could be elucidated. METHODS: Patients with treated CD from 2011 to 2023 were included. The perioperative and long-term characteristics of CD patients with and without recurrence were assessed using univariable and multivariable analyses. RESULTS: Of 383 patients with CD from 26 surgeons achieving postoperative remission, 288 (75.2%) maintained remission at last follow-up while 95 (24.8%) showed recurrence (median time to recurrence 9.99 ± 1.34 years). Patients with recurrence required longer postoperative hospital stays (5 ± 3 vs 4 ± 2 days, P = .002), had larger average tumor volumes (1.76 ± 2.53 cm 3 vs 0.49 ± 1.17 cm 3 , P = .0001), and more often previously failed prior treatment (31.1% vs 14.9%, P = .001) mostly being prior surgery. Multivariable hazard prediction models for tumor recurrence found younger age (odds ratio [OR] = 0.95, P = .002) and Knosp grade of 0 (OR = 0.09, reference Knosp grade 4, P = .03) to be protective against recurrence. Comparison of Knosp grade 0 to 2 vs 3 to 4 showed that lower grades had reduced risk of recurrence (OR = 0.27, P = .04). Other factors such as length of stay, surgeon experience, prior tumor treatment, and Knosp grades 1, 2, or 3 failed to reach levels of statistical significance in multivariable analysis. CONCLUSION: This multicenter study centers suggests that the strongest predictors of recurrence include tumor size/invasion and age. This insight can help with patient counseling and prognostication. Long-term follow-up is necessary for patients, and early treatment of small tumors may improve outcomes.
A Clinical Diagnostic Test for Calcium Release Deficiency Syndrome
Ni, Mingke , Saenen, Johan , Hoeksema, Wiert F. , Antiperovitch, Pavel , Arnaud, Marine , Tian, Shanshan, Sun, Bo , Estillore, John Paul , Wang, Ruiwu , Khan, Habib , Roston, Thomas M. , Mazzanti, Andrea , Giudicessi, John, Siontis, Konstantinos C. , Alak, Aiman, Acosta, J. Gabriel , Menon, Syamkumar M. Divakara, Tan, Nigel S. , Vivekanantham, Hari , Pandya, Tanvi, Cunningham, Jennifer , Gula, Lorne J. , Wong, Jorge , Amit, Guy , Scheinman, Melvin M. , Ackerman, Michael J. , Priori, Silvia G. , Sacher, Frédéric , Nof, Eyal , Glikson, Michael , Wilde, Arthur A.M. , Jensen, Henrik Kjærulf , Chen, S.R. Wayne , Roberts, Jason D. , Jensen, Henrik Kjærulf , Mazzanti, Andrea , Priori, Silvia , Dadon, Ziv , Ormerod, Julian O.M. , Tadros, Rafik , Christiansen, Morten Krogh , Steinberg, Christian , Giudicessi, John R. , Werf, Christian van der , Nazer, Babak , Krahn, Andrew D. , Gollob, Michael H. , Healey, Jeff S. , Glikson, Michael , Watkins, Hugh , Postema, Pieter G. , Belhassen, Bernard

Mayo Clinic

JAMA | June 20, 2024 | Volume: 332 | Issue: 3 | Pages: 204

10.1001/jama.2024.8599 | PMID 38900490 Get It

Importance Sudden death and cardiac arrest frequently occur without explanation, even after a thorough clinical evaluation. Calcium release deficiency syndrome (CRDS), a life-threatening genetic arrhythmia syndrome, is undetectable with standard testing and leads to unexplained cardiac arrest. Objective To explore the cardiac repolarization response on an electrocardiogram after brief tachycardia and a pause as a clinical diagnostic test for CRDS. Design, Setting, and Participants An international, multicenter, case-control study including individual cases of CRDS, 3 patient control groups (individuals with suspected supraventricular tachycardia; survivors of unexplained cardiac arrest [UCA]; and individuals with genotype-positive catecholaminergic polymorphic ventricular tachycardia [CPVT]), and genetic mouse models (CRDS, wild type, and CPVT were used to define the cellular mechanism) conducted at 10 centers in 7 countries. Patient tracings were recorded between June 2005 and December 2023, and the analyses were performed from April 2023 to December 2023. Intervention Brief tachycardia and a subsequent pause (either spontaneous or mediated through cardiac pacing). Main Outcomes and Measures Change in QT interval and change in T-wave amplitude (defined as the difference between their absolute values on the postpause sinus beat and the last beat prior to tachycardia). Results Among 10 case patients with CRDS, 45 control patients with suspected supraventricular tachycardia, 10 control patients who experienced UCA, and 3 control patients with genotype-positive CPVT, the median change in T-wave amplitude on the postpause sinus beat (after brief ventricular tachycardia at ≥150 beats/min) was higher in patients with CRDS ( P &amp;lt; .001). The smallest change in T-wave amplitude was 0.250 mV for a CRDS case patient compared with the largest change in T-wave amplitude of 0.160 mV for a control patient, indicating 100% discrimination. Although the median change in QT interval was longer in CRDS cases ( P = .002), an overlap between the cases and controls was present. The genetic mouse models recapitulated the findings observed in humans and suggested the repolarization response was secondary to a pathologically large systolic release of calcium from the sarcoplasmic reticulum. Conclusions and Relevance There is a unique repolarization response on an electrocardiogram after provocation with brief tachycardia and a subsequent pause in CRDS cases and mouse models, which is absent from the controls. If these findings are confirmed in larger studies, this easy to perform maneuver may serve as an effective clinical diagnostic test for CRDS and become an important part of the evaluation of cardiac arrest.